



Evaluation Report for Category B, Subcategory 7.0 Application

Application Number: 2022-0652
Application: Reinstatement of Registered Product
Product: Hartz Ultraguard Flea & Tick Collar for Large Dogs
Registration Number: 29475
Active ingredient (a.i.): Tetrachlorvinphos
PMRA Document Number: 3464138

Background

As per Special Review Decision (SRD2021-01, *Tetrachlorvinphos and Its Associated End-Use Products*), residential postapplication dermal non-cancer and cancer risks resulting from exposure to pet collars containing tetrachlorvinphos were not shown to be acceptable. In addition, risks were not shown to be acceptable for exposure when applying pet collars. Therefore, all flea and tick pet collar products, including Hartz Ultraguard Flea & Tick Collar for Large Dogs, were cancelled due to application and postapplication risks.

Purpose of Application

The purpose of this application was to reinstate the registration of Hartz Ultraguard Flea & Tick Collar for Large Dogs, by addressing the health risks identified in SRD2021-01.

Chemistry Assessment

Hartz UltraGuard Reflective Flea & Tick Collar for Large Dogs is formulated as a slow-release generator containing containing tetrachlorvinphos at a concentration of 14.55%. This end-use product has a density of 1.15 g/cm³. The chemistry requirements for this product have been fulfilled.

Health Assessments

Information pertaining to the acute hazard profile of the end-use product, as well as available companion animal safety studies, was reviewed to support the request for registration reinstatement. With respect to the safety of animals wearing the collar, no significant concerns were identified from the available companion animal safety studies. With respect to the acute hazard profile, due to the product design, the collars are not expected to pose acute oral or inhalation toxicity hazards, or result in eye irritation. The active ingredients tetrachlorvinphos is of low acute toxicity via the dermal route and only slightly irritating to the skin; as such, collars impregnated with tetrachlorvinphos are not expected to result in systemic toxicity or irritation via the dermal route. However, the tetrachlorvinphos has been classified as a dermal sensitizer, and the available dermal sensitization study conducted with collars impregnated with tetrachlorvinphos failed to conclusively demonstrate that the collars do not

pose a dermal sensitization hazard due to limitations in the conduct of the study. This uncertainty is of particular concern given the degree of direct dermal contact of both humans and pets associated with the use of pet collars. Therefore, in order for the reinstatement of these products to be considered in the future, additional information would be required to conclusively demonstrate that the collars do not pose a dermal sensitization hazard.

Exposure assessments included previously reviewed data from the Special Review of tetrachlorvinphos (SRD2021-01) and a new *in vitro* dermal absorption study, which was relied upon to refine the dermal absorption value from 22% to 9%. Updated health risk assessments lead to the conclusion that non-cancer risks of concern are expected for applicators in commercial settings (Calculated Margin of Exposure (MOE) < Target MOE). Cancer risks of concern ($\geq 1 \times 10^{-6}$) were also identified for adults, youth and children from residential postapplication dermal and aggregate exposures. The risks of concern could not be further mitigated with the available data. Therefore, re-instatement of this product cannot be supported.

A dietary risk assessment was not required for this application.

Environmental Assessment

An environmental assessment was not required for this application.

Value Assessment

The reinstatement of registration for Hartz UltraGuard Flea & Tick Collar for Large Dogs was supported based on extrapolation from previously registered uses of the same product to kill fleas and for five moths and ticks for four months. The reinstatement of this product will maintain an alternative for pet owners to kill fleas and ticks on large dogs.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found that the health risks associated with the reinstatement of Hartz Ultraguard Flea & Tick Collar for Large Dogs, are not shown to be acceptable. This end-use product will expire on March 3, 2024.

References

PMRA Document Number	Reference
3425376	1997, Dermal Sensitization Test Buehler Method, DACO: 4.6.6
3425380	1993, Domestic Animal Safety Effect of a Single 2x Dose Pump Spray Treatment on Dogs, DACO: 4.6.9,86 - 1,870.7200, IIIA 7.10
3425382	1993, Domestic Animal Safety Effect of a Single 2x-Dose Aerosol Spray Treatment on Dogs, DACO: 4.6.9,86 - 1,870.7200, IIIA 7.10
3425383	1998, Hartz Mountain Domestic Animal Safety Study Effect of Three, 3x Dose Aerosol Spray Treatments on Dogs, DACO: 4.6.9,86 - 1,870.7200, IIIA 7.10
3426892	2017, Weight Loss Study of Rabon Release from HUG Flea & Tick Collar, DACO: 4.6.9,86 - 1,870.7200, IIIA 7.10
1841091	1992, Collar Safety Evaluation Test No. 1103, DACO: 4.9
1841092	1976, To Evaluate Cholinesterase Depression in Dogs by 14.5% Rabon Insecticide Flea Collars Submitted by the Hartz Mountain Corporation, DACO: 4.9
1841095	1971, Skin and Eye Irritancy Studies of Gardona Pet Collar in Dogs, DACO: 4.9
3309376	2021, In Silico Predictions of Dermal Absorption of Tetrachlorvinphos in Rat and Human, DACO: 5.8
3309377	2021, The In Vitro Percutaneous Absorption of Radiolabelled Tetrachlorvinphos at Three Concentrations in Aqueous and Lipid Vehicles through Human and Rat Split-Thickness Skin, DACO: 5.8
3335747	2022, Estimated Dermal Penetration of Tetrachlorvinphos (TCVP) in Humans Based on In Vitro and In Vivo Data, DACO: 5.8
3335748	2022, The In Vitro Percutaneous Absorption of Radiolabelled Tetrachlorvinphos (TCVP) at Three Concentrations in Aqueous and Lipid Vehicles through Human and Rat Split-Thickness Skin, DACO: 5.8

© His Majesty the King in Right of Canada, as represented by the Minister of Health Canada, 2023

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.